Attend the FiercePharmaMarketing Forum
This is a can't-miss event! Save 15% with promo code FPMF2018
Emotion is a strong decision driver, especially in healthcare—so important, in fact, that Havas Health & You has launched a new agency to focus on it.
Apple's latest move into EHRs may be its biggest healthcare play yet—and it could help pharma companies open direct channels to consumers.
Pfizer and Merck KGaA have suffered another setback with immuno-oncology med Bavencio—and this one’s raising some eyebrows.
A recently released FDA document shows that Pfizer's troubled fill-finish plant in Kansas was cited for continuing to repeat mistakes already cited by the…
Sources have told Reuters that Novartis is preparing to auction off its U.S. generics pills business.
Biogen and UCB are already rumored to be eyeing an Acorda buyout. But one analyst thinks a host of other major players could join their ranks.
Despite competitors' efforts to pick up market share, an analyst figures J&J's Remicade will dominate the market again in 2018.
Astellas buys Universal Cells, Teva is affected by Celltrion's manufacturing problem, Korea rolls out a digital health initiative.
Vertex has cancelled plans to test an investigational triple combo at several sites in France.
Repeated drug price hikes have caught plenty of criticism lately, but the attention isn't dissuading everyone.